Oral Answers to Questions

Heidi Allen Excerpts

Wednesday 21st November 2018 Commons Chamber

[The Prime Minister]

The right hon. Gentleman is absolutely right about the December joint report. The issue of what the processes in the United Kingdom would be when it comes to looking at the regulations is a matter for the United Kingdom to determine; it is for us to determine both our parliamentary decisions on that and the Stormont lock that was expressed in the December joint report. As the right hon. Gentleman will also know, the lock in the December joint report referred to a decision being taken by the Northern Ireland Executive and the Assembly, which sadly are not in place today.

[Heidi Allen (South Cambridgeshire) (Con)]

On Monday, at an event for cystic fibrosis sufferers organised by my hon. Friend the Member for Dudley North (Ian Austin), I heard something that I never want to hear again: a young woman in her 30s actively researching funeral plans because she has cystic fibrosis and knows there is no cure. My question is about the conversation between the National Institute for Health and Care Excellence, NHS England and Vertex, which has been at an impasse for almost three years now, about access to Orkambi for patients who need it. Pharmaceutical companies are of course entitled to make profit, and research and development is expensive and lengthy, but now that we have reached the point at which the Health and Social Care Committee is having to ask for transparency on the finances to try to break the impasse, we know we have to do something differently. Looking at the huge global forward profits for Vertex, will the Prime Minister personally work with the Health Secretary to break this impasse and get Orkambi to those patients who are desperate to relieve their cystic fibrosis symptoms?

[The Prime Minister]

My hon. Friend’s question is an important one, which has been raised in the House before. I recognise the concern about the length of time it has taken to work on this issue. The Department of Health and Social Care is working with NICE and the NHS. I believe that they have made the single biggest drug offer in the history of the NHS to Vertex, the pharma company; and Vertex needs to work with NICE to get this approved. I will ensure that the concern expressed by my hon. Friend and that I know exists in relation to this matter is fully made clear to the Department of Health and Social Care in the work that it is doing with NICE, the NHS and the pharma company order to ensure that the result is of benefit to the patients who are looking desperately for this drug.